Tryptophan MRI in People With Schizophrenia and Healthy Controls
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02067975|
Recruitment Status : Completed
First Posted : February 20, 2014
Last Update Posted : February 7, 2020
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Tryptophan Drug: Placebo||Phase 2 Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||68 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls|
|Study Start Date :||September 2014|
|Actual Primary Completion Date :||December 2019|
|Actual Study Completion Date :||December 2019|
Active Comparator: tryptophan
6gm of tryptophan at least two weeks apart at time zero of 7 hour visits 2 and 3
Placebo Comparator: Placebo
Placebo will be a liquid drink without tryptophan. 6mg at least two weeks apart at time zero of the 7 hour visits 2 and 3.
- Visual memory, attention, and processing speed scores on the Relational and Item Specific Encoding Task (RISE). [ Time Frame: at least two weeks ]Tryptophan-induced elevated KYNA levels transiently impair performance on neuropsychological measures of verbal and visual memory, attention, and processing speed.
- Dorsolateralhippcampal fMRI activation and connectivity using the Relational and Item Specific Encoding Task (RISE). [ Time Frame: at least two weeks ]Tryptophan-induced elevated KYNA levels alters dorsolateralhippcampal fMRI activation and connectivity during the performance of the relational memory task RISE.
- Glutamate levels using fMRI [ Time Frame: at least two weeks ]Tryptophan-induced elevated KYNA levels alter 1H-MRS measures of glutamate levels in the medial prefrontal cortex (mPFC), a brain region involved in attention and processing speed behaviors, default mode network activity, and sensitive to changes in KYNA levels.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02067975
|United States, Maryland|
|Maryland Psychiatric Research Center|
|Catonsville, Maryland, United States, 21228|
|Principal Investigator:||Robert W Buchanan, M.D.||University of Maryland, College Park|